Blue Arbor’s RESTORE Neuromuscular Interface System Receives FDA Breakthrough Device Designation & TAP Enrolment
Shots:
- US FDA granted BTD designation to Blue Arbor’s RESTORE Neuromuscular Interface System and accepted for Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot (enables FDA and medical device sponsors collaboration to accelerate development and commercialization of innovative devices in breakthrough program)
- RESTORE, a Robotic Prosthetic control system that creates effortless coordination between the Patient’s Residual muscles and Nervous system to prosthetic upper limbs to reinstate the natural function of the arm
- The device enables independent movement of wrist, arms, and elbow joints surpassing surface skin electrodes; constant motor signal captured over past 5 yrs in early feasibility human trials
Ref: Blue Arbor | Image: Blue Arbor
Related News:- Simpson’s Acolyte Image Guided Crossing and Re-Entry Catheter System Gains the US FDA’s Breakthrough Device Designation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
